Compared to other anticoagulants of the same type, the anti-vitamin K Préviscan increases the risk of immuno-allergic side effects.
The end of a monopoly? To prevent a cardiovascular incident, the vast majority of at-risk patients receive Préviscan (fluindione). The approach is effective. But compared to other types of anti-vitamin K, it increases the likelihood of serious side effects.
AVKs help slow blood clotting. It is for this reason that they are indicated for the prevention of an incident of the infarction type in persons suffering from atrial fibrillation, venous thrombosis or pulmonary embolism.
Fluindione clearly dominates the French market. 92% of patients on AVK receive this molecule. But compared to other available drugs, this is associated with a higher frequency of severe side effects – although they are rare. This was shown by a pharmacovigilance survey conducted by the Lyon Regional Center (Rhône). On June 19, the National Medicines Safety Agency (ANSM) calls on health professionals to be cautious.
Discontinuation of treatment possible
Faced with warfarin or acenocoumarol, surveillance experts have observed more severe immuno-allergic attacks with Préviscan. This phenomenon occurs during the first 6 months of treatment.
These symptoms can manifest themselves in classic forms, such as skin abnormalities (eczema, redness, swelling, etc.), respiratory discomfort or even fever. But patients can also suffer from liver or kidney damage. In the most severe cases, kidney failure may develop. The urine volume is suddenly reduced and unusual fatigue develops.
The appearance of these signs justifies meeting with your attending physician to discuss a change in treatment. Because this reflex improves symptoms and limits the risk of chronic damage.
In view of this increased risk, the ANSM asks healthcare professionals to favor alternatives to Préviscan. Caution is not exaggerated: more than 3 million people are on treatment. When therapy has already started, on the other hand, it is better to maintain the habits. Reinforced surveillance must then be put in place.
>> Consult our “Treatment” file: Anticoagulants: avoid thrombosis without too much risk of bleeding
.
